Is Biophytis (OTC-BPTS.Y) undervalued or overvalued?

A clear undervalued or overvalued classification is not currently available in the latest data file.

How is the financial health of Biophytis?

The current financial health read for Biophytis (OTC-BPTS.Y) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Biophytis's next earnings date?

The next earnings date currently listed for Biophytis (OTC-BPTS.Y) is September 25, 2026.

Does Biophytis (OTC-BPTS.Y) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Biophytis (OTC-BPTS.Y)?

The current P/E ratio listed for Biophytis (OTC-BPTS.Y) is -0.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Biophytis?

The current market capitalization listed for Biophytis is 1.601 M.

What is the enterprise value of Biophytis?

The current enterprise value listed for Biophytis is 7.877 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Biophytis?

The ticker symbol for Biophytis is OTC-BPTS.Y, and the stock is listed on OTC Markets.

Where is Biophytis (OTC-BPTS.Y) listed?

Biophytis (OTC-BPTS.Y) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Biophytis?

The current debt-to-total-capital ratio listed for Biophytis is 85.3%, which helps investors evaluate the company’s financing structure and leverage profile.

Biophytis (BPTSY) Fair Value & Stock Analysis

Q: What is the fair value of Biophytis (OTC-BPTS.Y) stock?

A fair value estimate for Biophytis (OTC-BPTS.Y) is not currently available in the latest data file.

Q: What is the analyst price target for OTC-BPTS.Y stock?

An analyst price target for Biophytis (OTC-BPTS.Y) is not currently available in the latest data file.

Biophytis (BPTSY)

Biophytis S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing therapies intended to slow degenerative processes and support functional outcomes in age-related diseases. Its lead candidate, BIO101, is being studied across several potential uses, including obesity, respiratory infections related to COVID-19, sarcopenia, and Duchenne muscular dystrophy. The company has a collaboration with AFM-Telethon related to BIO101 development for Duchenne muscular dystrophy, and it also works with LynxKite Technologies Pte Ltd on AI-driven drug discovery for longevity-focused therapies. The listed security is an OTC Markets depositary receipt tied to Biophytis S.A., rather than ordinary common equity.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-BPTS.Y	—	—	—	—	—	—	Weak	—	—	—	0.0%	September 25, 2026	-0.2x	-0.2x	—	1.601 M	7.877 M	85.3%	—	-25.4	—	79.4%